JP2017538672A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538672A5
JP2017538672A5 JP2017522532A JP2017522532A JP2017538672A5 JP 2017538672 A5 JP2017538672 A5 JP 2017538672A5 JP 2017522532 A JP2017522532 A JP 2017522532A JP 2017522532 A JP2017522532 A JP 2017522532A JP 2017538672 A5 JP2017538672 A5 JP 2017538672A5
Authority
JP
Japan
Prior art keywords
seq
cmv
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017522532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538672A (ja
JP6942313B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/074269 external-priority patent/WO2016062720A1/en
Publication of JP2017538672A publication Critical patent/JP2017538672A/ja
Publication of JP2017538672A5 publication Critical patent/JP2017538672A5/ja
Application granted granted Critical
Publication of JP6942313B2 publication Critical patent/JP6942313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017522532A 2014-10-22 2015-10-20 Cmv由来改変ウイルス様粒子 Active JP6942313B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14189897 2014-10-22
EP14189897.3 2014-10-22
EP15184192 2015-09-08
EP15184192.1 2015-09-08
PCT/EP2015/074269 WO2016062720A1 (en) 2014-10-22 2015-10-20 Modified virus-like particles of cmv

Publications (3)

Publication Number Publication Date
JP2017538672A JP2017538672A (ja) 2017-12-28
JP2017538672A5 true JP2017538672A5 (enExample) 2018-11-22
JP6942313B2 JP6942313B2 (ja) 2021-09-29

Family

ID=54337283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522532A Active JP6942313B2 (ja) 2014-10-22 2015-10-20 Cmv由来改変ウイルス様粒子

Country Status (20)

Country Link
US (3) US10532107B2 (enExample)
EP (1) EP3209326A1 (enExample)
JP (1) JP6942313B2 (enExample)
KR (2) KR102775741B1 (enExample)
CN (2) CN108064276B (enExample)
AU (1) AU2015335027B2 (enExample)
CA (1) CA2963709A1 (enExample)
CL (1) CL2017000987A1 (enExample)
CO (1) CO2017004119A2 (enExample)
IL (1) IL251532B (enExample)
MA (1) MA40824A (enExample)
MX (1) MX387985B (enExample)
MY (1) MY187462A (enExample)
NZ (1) NZ731205A (enExample)
PE (1) PE20171133A1 (enExample)
PH (1) PH12017500727A1 (enExample)
RU (1) RU2706970C2 (enExample)
SG (2) SG10201903538YA (enExample)
TN (1) TN2017000133A1 (enExample)
WO (1) WO2016062720A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
US10946078B2 (en) * 2016-04-27 2021-03-16 Benchmark Animal Health Ltd. Treatment of canine atopic dermatitis
WO2017186808A1 (en) * 2016-04-27 2017-11-02 Allergy Therapeutics (Uk) Limited Treatment of peanut allergy
EP3592378A1 (en) * 2017-03-07 2020-01-15 Universität Zürich Treatment of pruritus in horses
US20210079054A1 (en) * 2017-12-11 2021-03-18 Ubi Us Holdings, Llc. Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
CA3093709C (en) * 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
MA52180A (fr) 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta
AU2019278596A1 (en) 2018-05-28 2020-12-24 Evax Ag Treatment of urticaria
KR20210110318A (ko) * 2018-12-20 2021-09-07 사이바 아게 융합에 의해 변형된 cmv의 바이러스-유사 입자
MX2021008035A (es) * 2018-12-31 2021-12-10 United Neuroscience Ltd Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña.
WO2021083766A1 (en) 2019-10-29 2021-05-06 Evax Ag Treatment of pruritus in horses
US20230038487A1 (en) * 2019-11-25 2023-02-09 The Regents Of The University Of California Modified viral therapeutics and uses thereof
WO2021260131A1 (en) 2020-06-25 2021-12-30 Saiba AG Virus-like particles of cmv modified by fusion
MX2023005446A (es) * 2020-11-11 2023-07-18 European Molecular Biology Laboratory Particulas virales modificadas para terapia genica.
JP2023550628A (ja) * 2020-11-23 2023-12-04 スカウト バイオ, インコーポレイテッド 抗原結合分子およびその使用
CN117534736B (zh) * 2020-12-15 2026-06-09 深圳赫兹生命科学技术有限公司 一种用于生产vlp重组疫苗的cmv病毒样颗粒及其制备方法
AU2023208356A1 (en) 2022-01-19 2024-06-13 Universität Bern Compositions of virus-like particles and microcrystalline tyrosine
CN114437211B (zh) * 2022-01-26 2024-03-12 南京麦西崴克生物科技有限公司 基于猫过敏原Fel d1的卵黄抗体的制备方法
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ-グルカン若しくはマンナンからなるか、又はこれを含む結合体
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
TW202424182A (zh) 2022-08-30 2024-06-16 瑞士商賽巴動物健康股份有限公司 經修飾的cmv類病毒粒子
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法
GB202400747D0 (en) * 2024-01-19 2024-03-06 Univ Dundee IL31-VLP and medical uses thereof
TW202536171A (zh) 2024-03-04 2025-09-16 德商百靈佳殷格翰獸藥股份有限公司 用於治療ngf相關病症之主動疫苗接種
WO2025186318A2 (en) 2024-03-06 2025-09-12 Elanco Us Inc. Veterinary compositions of modified virus-like particles of cmv and feline il-1beta mutein antigens

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
JP2002518033A (ja) * 1998-06-20 2002-06-25 ユナイティド バイオメディカル インコーポレイティド 農場動物の成長促進のための合成ソマトスタチン免疫原
EP1278542A2 (en) * 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
DE60230656D1 (de) 2001-11-07 2009-02-12 Cytos Biotechnology Ag Antigenraster welche il-5, il-13 oder eotaxin präshilen erkrankungen
JP4533626B2 (ja) 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
GB0228715D0 (en) * 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
AU2004255470B2 (en) 2003-07-10 2010-08-19 Cytos Biotechnology Ag Packaged virus-like particles
WO2005091753A2 (en) 2004-03-25 2005-10-06 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
ATE524561T1 (de) 2004-04-06 2011-09-15 Sinai School Medicine Verfahren zur bestimmung einer allergenreaktion unter verwendung von mikroarray-immunoassay- techniken
NZ554387A (en) * 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
JP4927762B2 (ja) * 2005-02-14 2012-05-09 ザイモジェネティクス, インコーポレイテッド Il−31アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
ES2424229T3 (es) * 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
AU2006325225B2 (en) * 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007113633A2 (en) 2006-04-03 2007-10-11 Pfizer Products Inc. Immunogenic compositions comprising cat allergen fel dl
EP2140880B1 (en) 2008-07-04 2012-11-14 HAL Allergy Holding B.V. Modification of allergens
CN107029223A (zh) * 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
HUP1100470A2 (en) 2011-08-30 2013-03-28 Mezoegazdasagi Biotechnologiai Kutatokoezpont Nanoparticle-based veterinary vaccine
CN102943087A (zh) * 2012-11-26 2013-02-27 中国农业科学院上海兽医研究所 兔出血症病毒新型亚单位疫苗及其制备方法
JP6190898B2 (ja) 2013-10-28 2017-08-30 株式会社日立製作所 サーバに接続されるシステム及び仮想マシンが動作しているサーバに接続されたシステムによる方法
MA40824A (fr) 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
US10556003B2 (en) * 2015-09-08 2020-02-11 Universität Zürich Treatment of insect bite hypersensitivity
CN108025059B (zh) 2015-09-08 2022-09-09 苏黎世大学 抗猫过敏的组合物
US10946078B2 (en) 2016-04-27 2021-03-16 Benchmark Animal Health Ltd. Treatment of canine atopic dermatitis
WO2017186808A1 (en) 2016-04-27 2017-11-02 Allergy Therapeutics (Uk) Limited Treatment of peanut allergy
KR20210110318A (ko) 2018-12-20 2021-09-07 사이바 아게 융합에 의해 변형된 cmv의 바이러스-유사 입자

Similar Documents

Publication Publication Date Title
RU2017111266A (ru) Модифицированные вирусоподобные частицы вируса мозаики огурца
Balke et al. Recent advances in the use of plant virus-like particles as vaccines
Shim et al. Sublingual delivery of vaccines for the induction of mucosal immunity
JP2015521467A5 (enExample)
JP2014530010A5 (enExample)
Song et al. Mucosal and systemic immune responses to influenza H7N9 antigen HA1–2 co-delivered intranasally with flagellin or polyethyleneimine in mice and chickens
Deng et al. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge
JP2015501840A5 (enExample)
JP2006504653A5 (enExample)
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
JP2011250797A5 (enExample)
JP2012501959A5 (enExample)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
JP2024504566A (ja) 核酸ワクチン
JP2019506175A5 (enExample)
JP2023518340A5 (enExample)
TW202202169A (zh) 預防嚴重急性呼吸症候群冠狀病毒第二型(sars-cov-2)感染的生物可降解奈米複合物疫苗及方法
Pan et al. A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh (αK): A phase II study
JP2010506926A5 (enExample)
Mansoor et al. Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice
JP2020534874A (ja) Cd4ヘルパーt細胞エピトープの融合ペプチドおよびそのワクチン
JP2015529677A5 (enExample)
Nie et al. Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice
Ding et al. A Universal Influenza Nanovaccine for “Mixing Vessel” Hosts Confers Potential Ability to Block Cross‐Species Transmission
Nagpal et al. Current clinical status of new COVID-19 vaccines and immunotherapy